Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1972 1
1973 3
1975 17
1976 13
1977 22
1978 29
1979 47
1980 76
1981 38
1982 59
1983 65
1984 92
1985 99
1986 96
1987 97
1988 110
1989 117
1990 151
1991 133
1992 165
1993 166
1994 182
1995 177
1996 212
1997 231
1998 259
1999 245
2000 293
2001 321
2002 321
2003 380
2004 440
2005 478
2006 535
2007 567
2008 658
2009 638
2010 746
2011 794
2012 921
2013 961
2014 963
2015 1066
2016 1048
2017 1081
2018 1225
2019 1199
2020 1350
2021 1473
2022 1437
2023 1410
2024 1114

Text availability

Article attribute

Article type

Publication date

Search Results

21,898 results

Results by year

Filters applied: . Clear all
Page 1
Hormone Therapy in Breast Cancer.
Drăgănescu M, Carmocan C. Drăgănescu M, et al. Chirurgia (Bucur). 2017 Jul-Aug;112(4):413-417. doi: 10.21614/chirurgia.112.4.413. Chirurgia (Bucur). 2017. PMID: 28862117 Free article. Review.
Hormonal therapy is mandatory for all patients with hormonereceptor- positive breast neoplasms. ...LHRH analogues are used in premenopausal patients in adjuvantcy and sometimes in case of recurrences. Around 50% of hormonereceptor- positive b …
Hormonal therapy is mandatory for all patients with hormonereceptor- positive breast neoplasms. ...LHRH analogue …
Soy Isoflavones and Breast Cancer Risk: A Meta-analysis.
Boutas I, Kontogeorgi A, Dimitrakakis C, Kalantaridou SN. Boutas I, et al. In Vivo. 2022 Mar-Apr;36(2):556-562. doi: 10.21873/invivo.12737. In Vivo. 2022. PMID: 35241506 Free PMC article. Review.
Numerous studies have examined the relationship between soy consumption and breast cancer but not the amount of consumption itself. We performed a systematic review of the literature in order to determine whether the amount of soy and isoflavones consumed has a p …
Numerous studies have examined the relationship between soy consumption and breast cancer but not the amount of consumption it …
[Hormone and breast cancer].
Gompel A. Gompel A. Presse Med. 2019 Oct;48(10):1085-1091. doi: 10.1016/j.lpm.2019.09.021. Epub 2019 Oct 26. Presse Med. 2019. PMID: 31662219 Review. French.
Pregnancy decreases the risk if at a young age but after 25 years may increase the risk. Combined menopause hormone treatment is associated to a greater risk than estrogens alone. Breast cancer associated with hormone treatment is estradiol receptor …
Pregnancy decreases the risk if at a young age but after 25 years may increase the risk. Combined menopause hormone treatment is asso …
Progesterone and Breast Cancer.
Trabert B, Sherman ME, Kannan N, Stanczyk FZ. Trabert B, et al. Endocr Rev. 2020 Apr 1;41(2):320-44. doi: 10.1210/endrev/bnz001. Endocr Rev. 2020. PMID: 31512725 Free PMC article. Review.
Synthetic progestogens (progestins) have been linked to increased breast cancer risk; however, the role of endogenous progesterone in breast physiology and carcinogenesis is less clearly defined. ...Given conflicting data related to the potential role of prog …
Synthetic progestogens (progestins) have been linked to increased breast cancer risk; however, the role of endogenous progeste …
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ. Burstein HJ, et al. J Clin Oncol. 2019 Feb 10;37(5):423-438. doi: 10.1200/JCO.18.01160. Epub 2018 Nov 19. J Clin Oncol. 2019. PMID: 30452337
RECOMMENDATIONS: The Panel recommends that women with node-positive breast cancer receive extended therapy, including an AI, for up to a total of 10 years of adjuvant endocrine treatment. ...Additional information can be found at www.asco.org/breast- …
RECOMMENDATIONS: The Panel recommends that women with node-positive breast cancer receive extended therapy, including a …
Sex steroid hormones and risk of breast cancer: a two-sample Mendelian randomization study.
Nounu A, Kar SP, Relton CL, Richmond RC. Nounu A, et al. Breast Cancer Res. 2022 Oct 8;24(1):66. doi: 10.1186/s13058-022-01553-9. Breast Cancer Res. 2022. PMID: 36209141 Free PMC article.
BACKGROUND: Breast cancer (BC) has the highest cancer incidence and mortality in women worldwide. Observational epidemiological studies suggest a positive association between testosterone, estradiol, dehydroepiandrosterone sulphate (DHEAS) and other se …
BACKGROUND: Breast cancer (BC) has the highest cancer incidence and mortality in women worldwide. Observational epidemi …
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, Shparyk Y, Cardona-Huerta S, Cheung KL, Philco-Salas MJ, Ruiz-Borrego M, Shao Z, Noguchi S, Rowbottom J, Stuart M, Grinsted LM, Fazal M, Ellis MJ. Robertson JFR, et al. Lancet. 2016 Dec 17;388(10063):2997-3005. doi: 10.1016/S0140-6736(16)32389-3. Epub 2016 Nov 29. Lancet. 2016. PMID: 27908454 Clinical Trial.
BACKGROUND: Aromatase inhibitors are a standard of care for hormone receptor-positive locally advanced or metastatic breast cancer. We investigated whether the selective oestrogen receptor degrader fulvestrant could improve progression-free survival co …
BACKGROUND: Aromatase inhibitors are a standard of care for hormone receptor-positive locally advanced or metastatic breast …
Hormone receptor-positive breast cancer and black race: does sex matter?
Eskander MF, Li Y, Bhattacharyya O, Tsung A, Oppong BA, Hamad A, Gatti-Mays M, Obeng-Gyasi S. Eskander MF, et al. Breast Cancer Res Treat. 2021 Nov;190(1):111-119. doi: 10.1007/s10549-021-06359-5. Epub 2021 Aug 12. Breast Cancer Res Treat. 2021. PMID: 34383180 Free PMC article.
PURPOSE: Black breast cancer patients have worse clinical outcomes than their White counterparts. There are few studies comparing clinical outcomes between Black male breast cancer (MBC) and female breast cancer (FBC) patients. ...Horm …
PURPOSE: Black breast cancer patients have worse clinical outcomes than their White counterparts. There are few studies compar …
Sequencing systemic therapy in hormone-receptor positive metastatic breast cancer: a modern paradigm.
Haddad SA, Dizon DS, Graff SL. Haddad SA, et al. Chin Clin Oncol. 2023 Aug;12(4):42. doi: 10.21037/cco-23-22. Epub 2023 Aug 10. Chin Clin Oncol. 2023. PMID: 37574571 Free article. Review.
Deaths from metastatic breast cancer continue to be a leading cause of global cancer mortality among women. The pace of advances in the treatment of hormone-receptor positive metastatic breast cancer (HR+ MBC) has introduced nuance …
Deaths from metastatic breast cancer continue to be a leading cause of global cancer mortality among women. The pace of …
21,898 results
You have reached the last available page of results. Please see the User Guide for more information.

Searches related to "hormone positive breast cancer"